A practical reference on drug affinity complex: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-04. Anything still debated is marked as such rather than presented as settled.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
sonication Also ultrasonication. The application of sound energy at ultrasonic frequencies in order to agitate particles in a chemical or biological sample. Intense acoustic vibrations produce pressure waves and cavitations that propagate through a liquid medium, thereby converting the sound energy to mechanical energy which can disperse solutes, disrupt intermolecular interactions, and break covalent bonds. At various amplitudes sonication can be used to increase the permeability of cell or nuclear membranes, a technique known as sonoporation, or to completely destroy them and release their contents for isolation and extraction. It has a wide variety of applications in industry and research, including creating nanoparticles such as liposomes, shearing DNA and proteins into smaller fragments, degassing liquids, and ultrasonic cleaning.
The structure of an ideal (infinitely long) single-walled carbon nanotube is that of a regular hexagonal lattice drawn on an infinite cylindrical surface, whose vertices are the positions of the carbon atoms. Since the length of the carbon-carbon bonds is fairly fixed, there are constraints on the diameter of the cylinder and the arrangement of the atoms on it. In the study of nanotubes, one defines a zigzag path on a graphene-like lattice as a path that turns 60 degrees, alternating left and right, after stepping through each bond. It is also conventional to define an armchair path as one that makes two left turns of 60 degrees followed by two right turns every four steps. On some carbon nanotubes, there is a closed zigzag path that goes around the tube. One says that the tube is of the zigzag type or configuration, or simply is a zigzag nanotube. If the tube is instead encircled by a closed armchair path, it is said to be of the armchair type, or an armchair nanotube. An infinite nanotube that is of one type consists entirely of closed paths of that type, connected to each other. The zigzag and armchair configurations are not the only structures that a single-walled nanotube can have. To describe the structure of a general infinitely long tube, one should imagine it being sliced open by a cut parallel to its axis, that goes through some atom A, and then unrolled flat on the plane, so that its atoms and bonds coincide with those of an imaginary graphene sheet—more precisely, with an infinitely long strip of that sheet.
== Hybrid models == From the beginning, the cyclol reaction was considered as a covalent analog of the hydrogen bond. Therefore, it was natural to consider hybrid models with both types of bonds. This was the subject of Wrinch's fourth paper on the cyclol model (1936), written together with Dorothy Jordan Lloyd, who first proposed that globular proteins are stabilized by hydrogen bonds. A follow-up paper was written in 1937 that referenced other researchers on hydrogen bonding in proteins, such as Maurice Loyal Huggins and Linus Pauling. Wrinch also wrote a paper with William Astbury, noting the possibility of a keto-enol isomerization of the >CαHα and an amide carbonyl group >C=O, producing a crosslink >Cα-C(OHα)< and again converting the oxygen to a hydroxyl group. Such reactions could yield five-membered rings, whereas the classic cyclol hypothesis produces six-membered rings. This keto-enol crosslink hypothesis was not developed much further.
A significant controversy arose with elements 102 through 106 in the 1960s and 1970s, as competition arose between the LBNL team (now led by Albert Ghiorso) and a team of Soviet scientists at the Joint Institute for Nuclear Research (JINR) led by Georgy Flyorov. Each team claimed discovery, and in some cases each proposed their own name for the element, creating an element naming controversy that lasted decades. These elements were made by bombardment of actinides with light ions. IUPAC at first adopted a hands-off approach, preferring to wait and see if a consensus would be forthcoming. But as it was also the height of the Cold War, it became clear that this would not happen. As such, IUPAC and the International Union of Pure and Applied Physics (IUPAP) created a Transfermium Working Group (TWG, fermium being element 100) in 1985 to set out criteria for discovery, which were published in 1991. After some further controversy, these elements received their final names in 1997, including seaborgium (106) in honour of Seaborg.
At about T+5 minutes was SECO (Sustainer Engine Cutoff) and Faith 7 entered orbit at 17,547 mph (7,844 m/s). After the spacecraft separated and turned around to orbit attitude, Cooper watched the spent Atlas lag behind and tumble for about eight minutes. Over Zanzibar on the first orbit, he learned that the orbital parameters were good enough for at least 20 orbits. As the spacecraft passed over Guaymas, Mexico still on the first orbit, capsule communicator Gus Grissom told Cooper the ground computers said he was "go for seven orbits." Atlas performance was overall excellent. The upgraded propulsion system worked well, with slightly above nominal booster engine thrust. Measurable propellant slosh occurred from T+55 to T+120 seconds, caused by slightly lower than nominal autopilot gains. The flight trajectory was slightly more lofted than nominal due to the DC voltage in the booster electrical system being about 0.7 volts above normal, but this was counteracted by the higher than nominal booster engine performance. BECO took place at T+132 seconds, escape tower jettison at T+141 seconds, and SECO at T+303 seconds.
Sources: en.wikipedia.org
Claus von Bülow (born Claus Cecil Borberg; 11 August 1926 – 25 May 2019) was a British lawyer, consultant and socialite. In 1982, he was convicted of attempting to murder his wife Sunny von Bülow (born Martha Sharp Crawford; 1932–2008) in 1979, which had left her in a temporary coma, and in 1980, when an alleged insulin overdose left her in a persistent vegetative state for the rest of her life. On appeal, both convictions were reversed, and von Bülow was found not guilty at his second trial.
The synthesis of luciferin exemplifies another strategy of isolating reaction partners, which is to take advantage of rarely-occurring, natural groups such as the 1,2-aminothiol, which appears only when a cysteine is the final N' amino acid in a protein. Their natural selectivity and relative bioorthogonality is thus valuable in developing probes specific for these tags. The above reaction occurs between a 1,2-aminothiol and a 2-cyanobenzothiazole to make luciferin, which is fluorescent. This luciferin fluorescence may then be quantified by spectrometry following a wash, and used to determine the relative presence of the molecule bearing the 1,2-aminothiol. If the quantification of non-1,2-aminothiol-bearing protein is desired, the protein of interest may be cleaved to yield a fragment with a N' Cys that is vulnerable to the 2-CBT.
Domesticated birds raised for meat and eggs, called poultry, are the largest source of animal protein eaten by humans; in 2003, 76 million tons of poultry and 61 million tons of eggs were produced worldwide. Chickens account for much of human poultry consumption, though domesticated turkeys, ducks, and geese are also relatively common. Many species of birds are also hunted for meat. Bird hunting is primarily a recreational activity except in extremely undeveloped areas. The most important birds hunted in North and South America are waterfowl; other widely hunted birds include pheasants, wild turkeys, quail, doves, partridge, grouse, snipe, and woodcock. Muttonbirding is also popular in Australia and New Zealand. Although some hunting, such as that of muttonbirds, may be sustainable, hunting has led to the extinction or endangerment of dozens of species. Other commercially valuable products from birds include feathers (especially the down of geese and ducks), which are used as insulation in clothing and bedding, and seabird faeces (guano), which is a valuable source of phosphorus and nitrogen. The War of the Pacific, sometimes called the Guano War, was fought in part over the control of guano deposits. Birds have been domesticated by humans both as pets and for practical purposes. Colourful birds, such as parrots and mynas, are bred in captivity or kept as pets, a practice that has led to the illegal trafficking of some endangered species. Falcons and cormorants have long been used for hunting and fishing, respectively.
== Notable academic journal articles == "Intracellular reduction of selenite into glutathione peroxidase... " - US National Library of Medicine - 2000 "Vestibular Dysfunction in DFNB1 Deafness" - US National Library of Medicine - 2011
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.